Advisory: Give yourself extra time when travelling by car to Toronto General Hospital, Princess Margaret Cancer Centre, or Toronto Rehab University Centre. City of Toronto construction on University Ave. may cause delays.
At UHN, we strive to deliver Compassionate Care & Caring. Learn more about the services and supports that are available to you throughout your journey.
Our UHN programs and services are among the most advanced in the world. We have grouped our physicians,
staff, services and resources into 10 medical programs to meet the needs of our patients and help us make
the most of our resources.
At the heart of everything we do at UHN are our Healthcare Professionals. Refer a patient to one of our 12 medical programs. Learn more about the resources and opportunities available for professional growth.
University Health Network has grown to be one of the largest research and teaching hospital networks in Canada - pioneers in improving the lives of patients. Our long history of health professions education at Toronto General, Toronto Western, Princess Margaret and Toronto Rehab hospitals has consistently advanced the science of education.
University Health Network is a health care and medical research organization in
Toronto, Ontario, Canada. The scope of research and complexity of cases at UHN has made us a national and international
source for discovery, education and patient care.
Being touched by illness affects us in different ways. Many people want to give back to the community
and help others. At UHN, we welcome your contribution and offer different ways you can help so you can find one that suits you.
The Newsroom is the source for media looking for information about UHN or trying to connect with one
of our experts for an interview. It's also the place to find UHN media policies and catch up on our news stories, videos, media releases,
podcasts and more.
Regeneration of the blood system through the transplantation of blood-forming stem cells (commonly referred to as bone marrow transplantation) is an effective treatment for a range of blood cell diseases, including leukemia. The transplantation of blood-forming stem cells and specific blood cell types is already being used in the clinic or under investigation for the treatment of an expanded list of diseases, such as cancers, autoimmune diseases and inflammation. Cells for these therapies are currently obtained from immune-matched donors or from the patients themselves. Although effective, reliance on donor and patient-derived cells limits the number of patients that can be treated and the benefit of these transplantation-based therapies. The generation of blood-forming stem cells and specific blood cell types from human pluripotent stem cells (hPSCs) would provide a new and potentially unlimited supply of these cells for treating a much broader patient population.
Using insights from blood cell development in different organisms, the Keller lab has successfully modelled human hematopoietic development from hPSCs differentiated in vitro. Through manipulation of specific signalling pathways, they have demonstrated that it is possible to generate the two major hematopoietic programs — primitive and definitive — which are known to develop in the embryo. While the main function of primitive hematopoiesis is to generate the cohort of blood cells required to sustain embryonic life, recent studies have shown that this program also contributes to a specialized immune cell population, the tissue-resident macrophage that persists in different organs into adulthood. These macrophages are thought to play important roles in maintaining normal organ function. Definitive hematopoiesis gives rise to all the hematopoietic cell types found in the adult, including the hematopoietic stem cell (HSC). Through our ability to specify these two programs, we have been able to develop protocols for the generation of most of the hematopoietic cells found in the embryo as well as in the adult. Additionally, we have been able to identify developmentally staged progenitors that display the properties of the progenitors that give rise to the HSC in the embryo. These advances have brought us an important step closer to generating hPSC-derived HSCs, immune cells and tissue-resident macrophages for the development of new cell-based therapies to treat different diseases.
Current projects include: